Core Viewpoint - DSS, Inc. has successfully closed a public offering, raising approximately $1.0 million in gross proceeds, which will be used for general corporate purposes including working capital [1][2]. Group 1: Offering Details - The public offering consisted of 900,000 shares of common stock priced at $1.00 per share [2]. - An overallotment option was granted to the underwriter, Aegis Capital Corp., allowing the purchase of an additional 135,000 shares, representing 15% of the shares sold in the offering [2]. - Aegis Capital Corp. served as the sole book-running manager for the offering [3]. Group 2: Regulatory Information - The offering was conducted under an effective shelf registration statement on Form S-3, previously filed with the SEC on October 31, 2024, and declared effective on November 5, 2024 [3]. Group 3: Company Overview - DSS, Inc. operates across multiple industries, including product packaging, biotechnology, commercial lending, and securities and investment management [5]. - The company focuses on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings [5].

Core Viewpoint - Healthcare Triangle, Inc. has entered into a Sales Agreement with Spartan Capital Securities for an at-the-market offering program, allowing the company to raise up to $20 million through the sale of its common stock [1][2]. Group 1: Sales Agreement Details - The Sales Agreement was executed on November 18, 2025, enabling Healthcare Triangle to offer and sell shares with an aggregate market value of up to $20 million [2]. - Shares may be sold on the Nasdaq Capital Market or other trading venues at prevailing market prices, providing flexible access to capital for the company's operational and financial strategy [2]. Group 2: Company Focus and Support - Healthcare Triangle is focused on strengthening its platform and expanding capabilities in cloud-based healthcare solutions [3]. - Spartan Capital Securities expresses support for Healthcare Triangle through the ATM program, indicating a commitment to the company's capital markets initiatives [3]. Group 3: Regulatory Compliance - The shares offered under the ATM program will be issued pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [4].

Core Viewpoint - Cyngn Inc. has successfully closed a registered direct offering, raising approximately $17.2 million through the sale of shares and pre-funded warrants at a price of $7.50 per share [1][3]. Group 1: Offering Details - The offering included the sale of 2,293,333 shares of Common Stock or Pre-Funded Warrants, with the public offering price set at $7.50 per share [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. - The transaction closed on June 30, 2025, and the net proceeds will be used for general corporate purposes and working capital [3]. Group 2: Regulatory and Legal Aspects - The offering was conducted under an effective shelf registration statement on Form S-3, which was filed with the SEC and declared effective on June 13, 2023 [4]. - Aegis Capital Corp. served as the exclusive placement agent for the offering, while Sichenzia Ross Ference Carmel LLP and Kaufman & Canoles, P.C. acted as legal counsel for the company and Aegis Capital Corp., respectively [3]. Group 3: Company Overview - Cyngn develops autonomous vehicle technology aimed at addressing challenges faced by industrial organizations, such as labor shortages and safety incidents [7]. - The company's DriveMod technology allows customers to integrate self-driving technology into their operations without significant upfront costs or infrastructure changes [8]. - DriveMod is currently available on specific models like Motrec MT-160 Tuggers and BYD Forklifts, with the Tugger capable of hauling up to 12,000 lbs and a typical payback period of less than 2 years [9].

Core Viewpoint - Cyngn Inc. has successfully closed a registered direct offering, raising approximately $15.0 million through the sale of shares and pre-funded warrants at a price of $5.01 per share [1][3]. Group 1: Offering Details - The offering included the sale of 2,994,012 shares of Common Stock and Pre-Funded Warrants, with the public offering price set at $5.01 per share [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised, with a minimal exercise price of $0.00001 [2]. - The transaction closed on June 27, 2025, and the net proceeds will be used for general corporate purposes and working capital [3]. Group 2: Legal and Regulatory Information - The offering was conducted under an effective shelf registration statement on Form S-3, which was declared effective by the SEC on June 13, 2023 [4]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC, providing further details about the offering [4]. Group 3: Company Overview - Cyngn develops autonomous vehicle technology aimed at addressing challenges faced by industrial organizations, such as labor shortages and safety incidents [7]. - The company's DriveMod technology allows customers to implement self-driving technology without significant upfront costs or infrastructure changes [8]. - DriveMod is currently available on specific models like Motrec MT-160 Tuggers and BYD Forklifts, with capabilities such as hauling up to 12,000 lbs and a payback period of less than 2 years [9].

Core Viewpoint - Cyngn Inc. has announced a registered direct offering of approximately $15.0 million in shares of Common Stock and pre-funded warrants at a price of $5.01 per share, aimed at raising capital for general corporate purposes and working capital [1][3]. Group 1: Offering Details - The offering includes the sale of 2,994,012 shares of Common Stock or Pre-Funded Warrants, with the public offering price set at $5.01 per share [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised, with a minimal exercise price of $0.00001 [2]. - The transaction is expected to close on or about June 27, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes and working capital [3]. Group 3: Company Background - Cyngn develops and deploys autonomous vehicle technology tailored for industrial organizations, addressing challenges such as labor shortages and safety incidents [8]. - The company's DriveMod technology allows customers to integrate self-driving technology into their operations without significant upfront costs or infrastructure changes [9]. - DriveMod products include the Tugger, which can haul up to 12,000 lbs, and the Forklift, designed for non-standard pallets, with a typical payback period of less than 2 years [10].

Core Insights - Spartan Capital Securities, LLC successfully completed a $3,788,000 private placement for Lipella Pharmaceuticals Inc. [1] - The proceeds will support Lipella's mission to develop innovative therapies for unmet medical needs and fund general corporate purposes [2] - Spartan Capital's CEO highlighted the strength of Lipella's vision and the firm's commitment to facilitating impactful investment opportunities [3] Company Overview - Lipella Pharmaceuticals is focused on developing groundbreaking clinical therapies aimed at significant medical needs [2] - Spartan Capital Securities is a full-service investment banking firm known for its expertise in capital raising and strategic advisory services [6] Transaction Details - Spartan Capital acted as the sole placement agent for the private offering [1][3] - Legal counsel for the transaction included Sichenzia Ross Ference Carmel LLP for the placement agent and Sullivan & Worcester LLP for Lipella Pharmaceuticals [3] - Further transaction details will be available in Lipella's Form 8-K to be filed with the U.S. Securities and Exchange Commission [4]

Group 1 - Spartan Capital Securities, LLC successfully completed a $3,788,000 private placement for Lipella Pharmaceuticals Inc. [1][2] - The proceeds will support Lipella's mission to develop innovative therapies for unmet medical needs and fund general corporate purposes [2] - Jonathan Kaufman, CEO of Lipella, is focused on advancing the company's clinical pipeline and transformative treatments [2] Group 2 - John Lowry, CEO of Spartan Capital, expressed honor in serving as the sole placement agent and highlighted Lipella's commitment to medical innovation [3] - The transaction reflects the strength of Lipella's vision and Spartan Capital's dedication to impactful investment opportunities [3] - Legal counsel for the transaction included Sichenzia Ross Ference Carmel LLP for the placement agent and Sullivan & Worcester LLP for Lipella [3] Group 3 - Further details on the transaction will be available in Lipella's Form 8-K, to be filed with the U.S. Securities and Exchange Commission [4] - The common shares and related warrants have not been registered under the Securities Act of 1933, limiting their sale until registration or exemption [5] - This press release does not constitute an offer to sell or solicit offers to buy the securities [6]

Core Insights - Spartan Capital Securities, LLC successfully completed a $15.2 million private placement for Healthcare Triangle, Inc. to support its expansion and digital transformation initiatives in the healthcare and life sciences sectors [1][2]. Group 1: Financial Details - The proceeds from the private placement will be utilized for strategic acquisitions, general corporate purposes, and working capital needs, enhancing Healthcare Triangle's mission in cloud enablement, cybersecurity, and data analytics solutions [2]. - Spartan Capital Securities played a significant role by placing $14.2 million of the total private placement, highlighting its strong position in the investment banking sector [2]. Group 2: Company Statements - John Lowry, CEO of Spartan Capital Securities, expressed honor in serving as Co-Placement Agent for Healthcare Triangle, emphasizing the company's leadership in digital innovation within healthcare and life sciences [3]. - The successful transaction reflects both Healthcare Triangle's strong vision and Spartan Capital's commitment to facilitating meaningful investment opportunities [3]. Group 3: Legal and Compliance - The securities involved in the offering, including common stock and various warrants, have not been registered under the Securities Act of 1933 or any state securities laws, and cannot be offered or sold in the U.S. without registration or an applicable exemption [4].